Supplemental Material for Tertiary Prevention in Cancer Care: Understanding and Addressing the Psychological Dimensions of Cancer During the Active Treatment Period

2015 ◽  
Keyword(s):  
Treatment Period ◽  
Active Treatment ◽  
Cancer Care ◽  
Tertiary Prevention ◽  
Psychological Dimensions

Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

2014 ◽  
Vol 22 (10) ◽  
pp. 2813-2819 ◽  
Author(s):  
Gianmauro Numico ◽  
Antonio Trogu ◽  
Antonella Cristofano ◽  
Alessandro Mozzicafreddo ◽  
Giulia Courthod ◽  
...  
Keyword(s):  
Active Treatment ◽  
Cancer Care ◽  
Poor Quality ◽  
Quality Cancer Care

scholarly journals Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males

2004 ◽  
Vol 59 (6) ◽  
pp. 357-360 ◽  
Author(s):  
Márcio Bernik ◽  
Antonio Hélio Guerra Vieira ◽  
Paula Villela Nunes
Keyword(s):  
Panic Disorder ◽  
Crossover Study ◽  
Treatment Period ◽  
Active Treatment ◽  
Clinical Management ◽  
Analog Scale ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Orgasmic Dysfunction ◽  
Carry Over

PURPOSE: To investigate whether bethanecol chloride may be an alternative for the clinical management of clomipramine-induced orgasmic dysfunction, reported to occur in up to 96% of male users. METHODS: In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized, double-blind, placebo-controlled, two-period crossover study. A visual analog scale was used to assess severity of the orgasmic dysfunction. RESULTS: A clear improvement was observed in the active treatment period. No placebo or carry-over effects were observed. CONCLUSION: These findings suggest that bethanecol chloride given 45 minutes before sexual intercourse may be useful for clomipramine-induced orgasmic dysfunction in males.

scholarly journals Male Hormonal Contraception: A Double-Blind, Placebo-Controlled Study

2008 ◽  
Vol 93 (7) ◽  
pp. 2572-2580 ◽  
Author(s):  
Ellen Mommers ◽  
Wendy M. Kersemaekers ◽  
Jörg Elliesen ◽  
Marc Kepers ◽  
Dan Apter ◽  
...  
Keyword(s):  
Treatment Period ◽  
Active Treatment ◽  
Hormonal Contraception ◽  
Sperm Concentration ◽  
Controlled Study ◽  
Double Blind ◽  
Testosterone Undecanoate ◽  
Treatment Groups ◽  
High Release ◽  
Mode Of Application

Abstract Background: This study was performed to assess spermatogenesis suppression and safety of a new combination of an etonogestrel (ENG) implant combined with testosterone undecanoate (TU) injections for male contraception. This is the first large placebo-controlled study for male hormonal contraception. Design and Study Subjects: In this double-blind, multicenter study, we randomly assigned 354 healthy men to receive either a low- or high-release ENG implant sc combined with im TU injections (750 mg every 10 or 12 wk or 1000 mg every 12 wk) or placebo implant and injections. Treatment duration was 42 or 44 wk and posttreatment follow-up at least 24 wk. Results: Overall, spermatogenesis was suppressed to 1 million/ml or less at wk 16 in 89% of men, with approximately 94% in two high-release ENG groups. Suppression was maintained up to the end of the treatment period in 91% of men. For all men who completed the treatment period, 3% never achieved 1 million/ml or less. Median recovery time to a sperm concentration above 20 million/ml was 15 wk (mean 17 wk, 95% confidence interval 16–18 wk). Treatment was well tolerated. As compared with the placebo group, more men in the active treatment groups reported adverse events such as weight gain, mood changes, acne, sweating, or libido change. For both spermatogenesis suppression and safety, differences were small between the active treatment groups. Conclusions: The combination of an ENG implant with TU injections is a well-tolerated male hormonal method, providing effective and reversible suppression of spermatogenesis. Although the results are good, there is still room for improvement, possibly by adjusting the dose regimen or changing the mode of application.

scholarly journals Alternative approach using miniscrew-anchored sliding jig to correct maxillary midline deviation in a patient with unilateral missing premolar

2019 ◽  
Vol 9 ◽  
pp. 111-116
Author(s):  
Kazuo Shimazaki ◽  
Zuisei Kanno ◽  
Takashi Ono
Keyword(s):  
Case Report ◽  
Treatment Period ◽  
Clinical Examination ◽  
Active Treatment ◽  
Orthodontic Treatment ◽  
Treatment Method ◽  
Posterior Segment ◽  
Chief Complaint ◽  
Molar Distalization ◽  
Alternative Approach

This case report describes the use of a miniscrew-anchored sliding jig (SJ) to distalize molars in a patient with maxillary midline deviation. A 41-year-old female presented with a chief complaint of maxillary midline deviation toward the left caused by prior orthodontic treatment involving unilateral extraction of a maxillary left premolar. Clinical examination revealed facial symmetry and a straight profile. The maxillary midline was deviated 2.5 mm to the left. The patient was treated with molar distalization using miniscrew-anchored SJs. Midline correction and alignment were obtained with maxillary unilateral distalization and mandibular full-arch distalization. The total active treatment period was 32 months. Appropriate occlusion and centered midlines were maintained after 29 months of retention. Our results suggest that the treatment method described herein is effective to distalize the unilateral posterior segment in either arch.

scholarly journals Efficacy and safety of fentanyl patch in cancer patients from the active treatment period to the terminal stage

2008 ◽  
Vol 3 (1) ◽  
pp. 201-208 ◽  
Author(s):  
Norio Watanabe ◽  
Mikio Yasumura ◽  
Naomasa Yoshida ◽  
Yoshihiko Kato ◽  
Chigusa Nakamura ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Treatment Period ◽  
Active Treatment ◽  
Efficacy And Safety ◽  
Fentanyl Patch ◽  
Terminal Stage

scholarly journals Efficacy and safety of fentanyl patch in cancer patients from the active treatment period to the terminal stage

2008 ◽  
Vol 3 (1) ◽  
pp. E1-E2
Author(s):  
Norio Watanabe ◽  
Mikio Yasumura ◽  
Naomasa Yoshida ◽  
Yoshihiko Kato ◽  
Chigusa Nakagawa ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Treatment Period ◽  
Active Treatment ◽  
Efficacy And Safety ◽  
Fentanyl Patch ◽  
Terminal Stage

scholarly journals Correction of Gummy Smile in a Patient of Vertical Maxillary Excess Using Absolute Anchorage System

2018 ◽  
Vol 8 ◽  
pp. 44-48
Author(s):  
Ekta Lahoti ◽  
Partha Pratim Choudhury ◽  
Ali Asger Nakib ◽  
Mukesh Kumar
Keyword(s):  
Adult Patient ◽  
Treatment Period ◽  
Female Patient ◽  
Surgical Therapy ◽  
Active Treatment ◽  
Orthodontic Treatment ◽  
Anchorage System ◽  
Transpalatal Arch ◽  
Maxillary Arch ◽  
Gummy Smile

This article presents the orthodontic treatment of a 24-year-old female patient with gummy smile and proclination along with a hyperdivergent profile. The patient showed excessive gingival display in both the anterior and posterior areas in the maxilla. Such situation in an adult patient often demands surgical therapy. However, due to patient reluctance toward surgery, the gummy smile was treated by the intrusion of the whole maxillary arch. After alignment and leveling, absolute anchorage system as well as a modified transpalatal arch was designed to achieve posterosuperior movement of the entire upper dentition. The active treatment period was 2.3 years.

Sign in / Sign up

Export Citation Format

Share Document